Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease

Neuropharmacology

Volumn 110, Issue , 2016, Pages 519-529

  Köfalvi, Attila ^a,b   Lemos, Cristina ^a   Martín Moreno, Ana M ^c,d   Pinheiro, Bárbara S ^a   García García, Luis ^e   Pozo, Miguel A ^e,f   Valério Fernandes, Ângela ^a   Beleza, Rui O ^a   Agostinho, Paula ^a,g   Rodrigues, Ricardo J ^a,b   Pasquaré, Susana J ^c,h   Cunha, Rodrigo A ^a,g   de Ceballos, María L ^c,d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c INSTITUTO CAJAL   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f PET Technology Institute   (Spain)

^g UNIVERSITY OF COIMBRA   (Portugal)

^h Instituto de Investigaciones Bioquimicas Bahia Blanca   (Argentina)

Author keywords

Anandamide (AEA); Cannabinoid CB2 receptor; Cerebral glucose uptake; Cyclooxygenase 2 (COX 2); Positron emission tomography (PET); amyloid

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ALPHA BETA HYDROLASE DOMAIN 6/12; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLOOXYGENASE 2; FATTY ACID AMIDASE; FLUORODEOXYGLUCOSE F 18; GP 1A; HYDROLASE; UNCLASSIFIED DRUG; AMIDE; AMYLOID PRECURSOR PROTEIN; ANANDAMIDE; APP PROTEIN, HUMAN; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR AFFECTING AGENT; CNR2 PROTEIN, MOUSE; CYCLOOXYGENASE 2 INHIBITOR; ENDOCANNABINOID; GLUCOSE; MONOXERUTIN; NOOTROPIC AGENT; PTGS2 PROTEIN, MOUSE;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOSE TRANSPORT; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; AGING; AGONISTS; AMYLOIDOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; DIAGNOSTIC IMAGING; DRUG EFFECTS; METABOLISM; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; ARACHIDONIC ACIDS; ASTROCYTES; BRAIN; CANNABINOID RECEPTOR MODULATORS; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOCANNABINOIDS; GLUCOSE; HYDROXYETHYLRUTOSIDE; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; NOOTROPIC AGENTS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB2; TISSUE CULTURE TECHNIQUES;

EID: 84988025899     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.03.015     Document Type: Article

References (79)

1. Agudo, J., Martin, M., Roca, C., Molas, M., Bura, A.S., Zimmer, A., Bosch, F., Maldonado, R., Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 53 (2010), 2629–2640, 10.1007/s00125-010-1894-6.
2. 2 receptors in the mouse hippocampus. Neurochem. Int. 60 (2012), 145–152.
3. Aso, E., Ferrer, I., Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front. Pharmacol., 5, 2014, 37, 10.3389/fphar.2014.00037.
4. 2 receptor antibodies. Br. J. Pharmacol., 163, 2011, 1113, 10.1111/j.1476-5381.2010.01139.x.
5. 2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 160 (2010), 467–479, 10.1111/j.1476-5381.2010.00729.x.
6. Bari, M., Bonifacino, T., Milanese, M., Spagnuolo, P., Zappettini, S., Battista, N., Giribaldi, F., Usai, C., Bonanno, G., Maccarrone, M., The endocannabinoid system in rat gliosomes and its role in the modulation of glutamate release. Cell. Mol. Life Sci. CMLS 68 (2011), 833–845, 10.1007/s00018-010-0494-4.
7. Bénard, G., Massa, F., Puente, N., Lourenço, J., Bellocchio, L., Soria-Gómez, E., Matias, I., Delamarre, A., Metna-Laurent, M., Cannich, A., Hebert-Chatelain, E., Mulle, C., Ortega-Gutiérrez, S., Martín-Fontecha, M., Klugmann, M., Guggenhuber, S., Lutz, B., Gertsch, J., Chaouloff, F., López-Rodríguez, M.L., Grandes, P., Rossignol, R., Marsicano, G., Mitochondrial CB receptors regulate neuronal energy metabolism. Nat. Neurosci. 15 (2012), 558–564, 10.1038/nn.3053.
8. 2 receptors in human brain inflammation. Br. J. Pharmacol. 153 (2008), 277–285, 10.1038/sj.bjp.0707505.
9. Berk, M., Dean, O., Drexhage, H., McNeil, J.J., Moylan, S., O'Neil, A., Davey, C.G., Sanna, L., Maes, M., Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med., 11, 2013, 74, 10.1186/1741-7015-11-74.
10. Branconnier, R.J., The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia. Psychopharmacol. Bull. 19 (1983), 212–219.
11. 2 form functional heteromers in brain. J. Biol. Chem. 287 (2012), 20851–20865, 10.1074/jbc.M111.335273.
12. 2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2 (2002), 69–82.
13. 2 receptor activation and the PPARγ pathway. Pharmacology 94 (2014), 1–12, 10.1159/000362689.
14. Dagon, Y., Avraham, Y., Ilan, Y., Mechoulam, R., Berry, E.M., Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 21 (2007), 2431–2441, 10.1096/fj.06-7705com.
15. Den Boon, F.S., Chameau, P., Schaafsma-Zhao, Q., van Aken, W., Bari, M., Oddi, S., Kruse, C.G., Maccarrone, M., Wadman, W.J., Werkman, T.R., Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 3534–3539, 10.1073/pnas.1118167109.
16. Di Marzo, V., De Petrocellis, L., Why do cannabinoid receptors have more than one endogenous ligand?. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 (2012), 3216–3228, 10.1098/rstb.2011.0382.
17. 1 receptor activation inhibits neuronal and astrocytic intermediary metabolism in the rat hippocampus. Neurochem. Int. 60 (2012), 1–8, 10.1016/j.neuint.2011.10.019.
18. 2 modulates axon guidance. PloS One, 8, 2013, e70849, 10.1371/journal.pone.0070849.
19. 1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119 (2003), 481–496.
20. Esposito, G., Iuvone, T., Savani, C., Scuderi, C., De Filippis, D., Papa, M., Di Marzo, V., Steardo, L., Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J. Pharmacol. Exp. Ther. 322 (2007), 1144–1152, 10.1124/jpet.107.121566.
21. Fowler, C.J., Björklund, E., Lichtman, A.H., Naidu, P.S., Congiu, C., Onnis, V., Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J. Enzyme. Inhib. Med. Chem. 28 (2013), 172–182, 10.3109/14756366.2011.643304.
22. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., Casellas, P., Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995), 54–61.
23. 2 cannabinoid receptors. Neuropharmacology 73 (2013), 388–396, 10.1016/j.neuropharm.2013.05.034.
24. Gierse, J.K., Hauser, S.D., Creely, D.P., Koboldt, C., Rangwala, S.H., Isakson, P.C., Seibert, K., Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305 (1995), 479–484.
25. Giovannini, M.G., Scali, C., Prosperi, C., Bellucci, A., Vannucchi, M.G., Rosi, S., Pepeu, G., Casamenti, F., Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis. 11 (2002), 257–274.
26. Glaser, S.T., Kaczocha, M., Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. J. Pharmacol. Exp. Ther. 335 (2010), 380–388, 10.1124/jpet.110.168831.
27. 2) selective agonists. J. Med. Chem. 56 (2013), 8224–8256, 10.1021/jm4005626.
28. 1). J. Pharmacol. Exp. Ther. 289 (1999), 1427–1433.
29. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., Cole, G., Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996), 99–102.
30. 2 receptor. Bioorg. Med. Chem. 7 (1999), 2905–2914.
31. Jakoby, P., Schmidt, E., Ruminot, I., Gutiérrez, R., Barros, L.F., Deitmer, J.W., Higher transport and metabolism of glucose in astrocytes compared with neurons: a multiphoton study of hippocampal and cerebellar tissue slices. Cereb. Cortex N. Y. N. 1991:24 (2014), 222–231, 10.1093/cercor/bhs309.
32. Jung, K.-M., Astarita, G., Yasar, S., Vasilevko, V., Cribbs, D.H., Head, E., Cotman, C.W., Piomelli, D., An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol. Aging 33 (2012), 1522–1532, 10.1016/j.neurobiolaging.2011.03.012.
33. Katona, I., Freund, T.F., Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 35 (2012), 529–558.
34. Kilkenny, C., Browne, W., Cuthill, I.C., Emerson, M., Altman, D.G., NC3Rs Reporting Guidelines Working Group, Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 160 (2010), 1577–1579, 10.1111/j.1476-5381.2010.00872.x.
35. Kuntner, C., Kesner, A.L., Bauer, M., Kremslehner, R., Wanek, T., Mandler, M., Karch, R., Stanek, J., Wolf, T., Müller, M., Langer, O., Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. MIB Off. Publ. Acad. Mol. Imaging 11 (2009), 236–240, 10.1007/s11307-009-0198-z.
36. 1 receptor knockout mice. Science 283 (1999), 401–404.
37. 2B receptor activation stimulates glucose uptake in the mouse forebrain. Purinergic Signal 11 (2015), 561–569, 10.1007/s11302-015-9474-3.
38. 1 receptor knockout mice as revealed by an optimized in vitro experimental approach. J. Neurosci. Methods 204 (2012), 366–373, 10.1016/j.jneumeth.2011.11.028.
39. 2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience 311 (2015), 253–267.
40. 2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus. Hippocampus 26 (2016), 275–281.
41. 2 cannabinoid receptor knockout in mice impairs contextual long-term memory and enhances spatial working memory. Neural Plast., 9817, 2016, 10.1155/2016/9817089.
42. Li, W., Blankman, J.L., Cravatt, B.F., A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J. Am. Chem. Soc. 129 (2007), 9594–9595.
43. Long, J.Z., Li, W., Booker, L., Burston, J.J., Kinsey, S.G., Schlosburg, J.E., Pavón, F.J., Serrano, A.M., Selley, D.E., Parsons, L.H., Lichtman, A.H., Cravatt, B.F., Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5 (2009), 37–44, 10.1038/nchembio.129.
44. Martín-Moreno, A.M., Brera, B., Spuch, C., Carro, E., García-García, L., Delgado, M., Pozo, M.A., Innamorato, N.G., Cuadrado, A., de Ceballos, M.L., Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation, 9, 2012, 8, 10.1186/1742-2094-9-8.
45. Matias, I., Marzo, V.D., Köfalvi, A., Endocannabinoids in energy homeostasis and metabolic disorders. Köfalvi, A., (eds.) Cannabinoids and the Brain, 2008, Springer, US, 277–316.
46. McGrath, J.C., Drummond, G.B., McLachlan, E.M., Kilkenny, C., Wainwright, C.L., Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br. J. Pharmacol. 160 (2010), 1573–1576, 10.1111/j.1476-5381.2010.00873.x.
47. Messier, C., Glucose improvement of memory: a review. Eur. J. Pharmacol. 490 (2004), 33–57, 10.1016/j.ejphar.2004.02.043.
48. Milton, N.G.N., Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 332 (2002), 127–130.
49. 2 type cannabinoid receptors at CNS synapses. Neuropharmacology 57 (2009), 356–368.
50. Mosconi, L., Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32 (2005), 486–510, 10.1007/s00259-005-1762-7.
51. Mulder, J., Zilberter, M., Pasquaré, S.J., Alpár, A., Schulte, G., Ferreira, S.G., Köfalvi, A., Martín-Moreno, A.M., Keimpema, E., Tanila, H., Watanabe, M., Mackie, K., Hortobágyi, T., de Ceballos, M.L., Harkany, T., Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain J. Neurol. 134 (2011), 1041–1060, 10.1093/brain/awr046.
52. Murataeva, N., Straiker, A., Mackie, K., Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br. J. Pharmacol. 171:6 (2014), 1379–1391, 10.1111/bph.12411 2014 Mar.
53. Murineddu, G., Lazzari, P., Ruiu, S., Sanna, A., Loriga, G., Manca, I., Falzoi, M., Dessì, C., Curzu, M.M., Chelucci, G., Pani, L., Pinna, G.A., Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J. Med. Chem. 49 (2006), 7502–7512, 10.1021/jm060920d.
54. Nicolussi, S., Chicca, A., Rau, M., Rihs, S., Soeberdt, M., Abels, C., Gertsch, J., Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent. Biochem. Pharmacol. 92 (2014), 669–689, 10.1016/j.bcp.2014.09.020.
55. Nguyen, V.H., Verdurand, M., Dedeurwaerdere, S., Wang, H., Zahra, D., Gregoire, M.-C., Zavitsanou, K., Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: a small animal PET imaging study with 18F-FDG. Brain Res. Bull. 87 (2012), 172–179, 10.1016/j.brainresbull.2011.11.011.
56. Pamplona, F.A., Menezes-de-Lima, O., Takahashi, R.N., Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice. Neurosci. Lett. 470 (2010), 33–37, 10.1016/j.neulet.2009.12.050.
57. Pascual, A.C., Martín-Moreno, A.M., Giusto, N.M., de Ceballos, M.L., Pasquaré, S.J., Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists. Exp. Gerontol. 60 (2014), 92–99, 10.1016/j.exger.2014.10.011.
58. Pavía, J., de Ceballos, M.L., Sanchez de la Cuesta, F., Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Fundam. Clin. Pharmacol. 12 (1998), 473–481.
59. Pertwee, R.G., Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 (2012), 3353–3363, 10.1098/rstb.2011.0381.
60. Ramírez, B.G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., de Ceballos, M.L., Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. Off. J. Soc. Neurosci. 25 (2005), 1904–1913, 10.1523/JNEUROSCI.4540-04.2005.
61. Rodríguez-Cueto, C., Benito, C., Fernández-Ruiz, J., Romero, J., Hernández-Gálvez, M., Gómez-Ruiz, M., Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br. J. Pharmacol. 171 (2014), 1472–1489, 10.1111/bph.12283.
62. 2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. J. Neuroendocrinol. 24 (2012), 1106–1119, 10.1111/j.1365-2826.2012.02325.x.
63. Ruiz-Valdepeñas, L., Benito, C., Tolón, R.M., Martínez Orgado, J.A., Romero, J., The endocannabinoid system and amyloid-related diseases. Exp. Neurol. 224 (2010), 66–73, 10.1016/j.expneurol.2010.03.024.
64. Rutter, G.A., Da Silva Xavier, G., Leclerc, I., Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem. J. 375 (2003), 1–16, 10.1042/BJ20030048.
65. Sánchez, C., de Ceballos, M.L., Gomez del Pulgar, T., Rueda, D., Corbacho, C., Velasco, G., Galve-Roperh, I., Huffman, J.W., Ramón y Cajal, S., Guzmán, M., Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61 (2001), 5784–5789.
66. Savinainen, J.R., Saario, S.M., Laitinen, J.T., The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol. (Oxf) 204 (2012), 267–276, 10.1111/j.1748-1716.2011.02280.x.
67. 2 receptors in a mouse model of Aβ amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One, 10(6), 2015, e0129618, 10.1371/journal.pone.0129618.
68. Sheng, W.S., Hu, S., Min, X., Cabral, G.A., Lokensgard, J.R., Peterson, P.K., Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49 (2005), 211–219, 10.1002/glia.20108.
69. 2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct. Funct., 2014, 1–18, 10.1007/s00429-014-0823-8.
70. Solas, M., Francis, P.T., Franco, R., Ramirez, M.J., CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol. Aging 34 (2013), 805–808, 10.1016/j.neurobiolaging.2012.06.005.
71. Sperling, R.A., Karlawish, J., Johnson, K.A., Preclinical Alzheimer disease-the challenges ahead. Nat. Rev. Neurol. 9 (2013), 54–58, 10.1038/nrneurol.2012.241.
72. Stella, N., Piomelli, D., Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425 (2001), 189–196, 10.1523/jneurosci.4540-04.2005.
73. Stella, N., Schweitzer, P., Piomelli, D., A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997), 773–778.
74. Teune, L.K., Bartels, A.L., de Jong, B.M., Willemsen, A.T.M., Eshuis, S.A., de Vries, J.J., van Oostrom, J.C.H., Leenders, K.L., Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov. Disord. Off. J. Mov. Disord. Soc. 25 (2010), 2395–2404, 10.1002/mds.23291.
75. 2 receptors. Science 310 (2005), 329–332, 10.1126/science.1115740.
76. Weisová, P., Concannon, C.G., Devocelle, M., Prehn, J.H.M., Ward, M.W., Regulation of glucose transporter 3 surface expression by the AMP-activated protein kinase mediates tolerance to glutamate excitation in neurons. J. Neurosci. Off. J. Soc. Neurosci. 29 (2009), 2997–3008, 10.1523/JNEUROSCI.0354-09.2009.
77. Wu, J., Bie, B., Yang, H., Xu, J.J., Brown, D.L., Naguib, M., Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging 34 (2013), 791–804, 10.1016/j.neurobiolaging.2012.06.011.
78. Zahs, K.R., Ashe, K.H., β-Amyloid oligomers in aging and Alzheimer's disease. Front. Aging Neurosci., 5, 2013, 28, 10.3389/fnagi.2013.00028.
79. Zhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E.L., Wu, J., Xi, Z.-X., Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E5007–E5015, 10.1073/pnas.1413210111.